Literature DB >> 34196726

[Cannabis and cannabinoids for the treatment of acute and chronic pain].

Michael Schäfer1, Sascha Tafelski2.   

Abstract

Since the Act on the medical use of cannabis, at which cannabis-based medicines and cannabinoids became law, there has been an exponential increase in prescriptions for the acquisition of cannabis for medical purposes. The aim of this leading article is to compile and assess the currently available relevant clinical evidence for the use of cannabis and cannabinoids for treatment of acute and chronic pain. Based on the systematic literature review "Cannabis-Potential and risks (CAPRIS)" commissioned by the German Federal Ministry of Health and the recently published recommendations of the European Pain Federation EFIC, this article aims to give an orientation aid for the decision-making process in the clinical routine.

Entities:  

Keywords:  Acute pain; Cannabidiol; Cannabinoid receptors; Chronic pain; Tetrahydrocannabinol

Mesh:

Substances:

Year:  2021        PMID: 34196726     DOI: 10.1007/s00101-021-00994-9

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  68 in total

1.  Effects of nabilone, a synthetic cannabinoid, on postoperative pain.

Authors:  Pierre Beaulieu
Journal:  Can J Anaesth       Date:  2006-08       Impact factor: 5.063

Review 2.  Understanding the evidence for medical cannabis and cannabis-based medicines for the treatment of chronic non-cancer pain.

Authors:  Gabrielle Campbell; Emily Stockings; Suzanne Nielsen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-11       Impact factor: 5.270

3.  Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial.

Authors:  T D Brisbois; I H de Kock; S M Watanabe; M Mirhosseini; D C Lamoureux; M Chasen; N MacDonald; V E Baracos; W V Wismer
Journal:  Ann Oncol       Date:  2011-02-22       Impact factor: 32.976

4.  Effects of moderate and high doses of marihuana on thermal pain: a sensory decision theory analysis.

Authors:  W C Clark; M N Janal; P Zeidenberg; G G Nahas
Journal:  J Clin Pharmacol       Date:  1981 Aug-Sep       Impact factor: 3.126

5.  Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis.

Authors:  D R Blake; P Robson; M Ho; R W Jubb; C S McCabe
Journal:  Rheumatology (Oxford)       Date:  2005-11-09       Impact factor: 7.580

6.  Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial.

Authors:  Jonathan S Berman; Catherine Symonds; Rolfe Birch
Journal:  Pain       Date:  2004-12       Impact factor: 6.961

Review 7.  Neuropathic pain.

Authors:  Luana Colloca; Taylor Ludman; Didier Bouhassira; Ralf Baron; Anthony H Dickenson; David Yarnitsky; Roy Freeman; Andrea Truini; Nadine Attal; Nanna B Finnerup; Christopher Eccleston; Eija Kalso; David L Bennett; Robert H Dworkin; Srinivasa N Raja
Journal:  Nat Rev Dis Primers       Date:  2017-02-16       Impact factor: 52.329

8.  [Cannabis medicines in pain management : Interim analysis of the survey accompanying the prescription of cannabis-based medicines in Germany with regard to pain as primarily treated symptom].

Authors:  P Cremer-Schaeffer; G Schmidt-Wolf; K Broich
Journal:  Schmerz       Date:  2019-10       Impact factor: 1.107

Review 9.  A critical review of the safety and antiemetic efficacy of delta-9-tetrahydrocannabinol.

Authors:  D M Cocchetto; L F Cook; A E Cato
Journal:  Drug Intell Clin Pharm       Date:  1981-11

10.  Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain.

Authors:  Donal J Buggy; Lynn Toogood; Shelagh Maric; Paul Sharpe; David G Lambert; David J Rowbotham
Journal:  Pain       Date:  2003-11       Impact factor: 6.961

View more
  1 in total

1.  [Cannabis- Summing it all up!]

Authors:  Matthias Karst
Journal:  Anaesthesist       Date:  2021-07-07       Impact factor: 1.041

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.